



ASX / Media Release  
31 January 2022

## Professor Alex Sinclair Increases Commitment to Invex and New Chairman Consultancy Agreement

---

**Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company)** a clinical-stage biopharmaceutical company focused on the development and commercialisation of Presendin™ (sustained release Exenatide) for neurological conditions relating to raised intracranial pressure, today announces Invex's Chief Scientific Officer and Executive Director, Professor Alexandra (Alex) Sinclair has increased her commitment to the Company effective from 1 March 2022, by entering into an employment agreement with the Company's UK subsidiary, Invex Therapeutics Ltd. In addition, the Company has entered into a new consultancy agreement with Non-Executive Chairman Dr Jason Loveridge, effective 1 February 2022.

Professor Sinclair will continue to provide expert input into the execution of the Company's planned Phase III clinical trial and in the development of new clinical indications by leveraging Invex's core strength in the treatment pressure-related brain disorders with GLP-1 receptor agonists such as Presendin™ with academic centres of excellence.

Professor Sinclair is a co-founder of Invex and currently acts as a consultant to the Company in her role as Chief Scientific Officer (CSO) and Executive Director. Professor Sinclair is a Clinician Scientist and Neurology Consultant in the Metabolic Neurology Group at the Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, The University of Birmingham, UK. She runs the Headache and Idiopathic Intracranial Hypertension (IIH) Service at University Hospital Foundation Trust. As part of her transition to Invex employment, Professor Sinclair has reduced her teaching and clinical commitments to the University of Birmingham and the Foundation Trust.

Dr Jason Loveridge, Chairman of Invex said "We are very pleased Alex has increased her time commitment to Invex and has accepted our offer of employment with the Company, where her exceptional knowledge and status as key opinion leader in the field of IIH will continue to be invaluable as we rapidly advance our preparations towards commencing our Phase III registration trial for Presendin™. With Alex's deep clinical and scientific peer networks across the globe, we anticipate interest in our trial, which aims to secure the first regulatory approved drug therapy for IIH, will be strong."

Additionally, Invex has entered into a new consultancy agreement with Jason Loveridge. Dr Loveridge will receive a Non-Executive Chairman fee and a consultancy fee via Invex's UK subsidiary, with a termination notice period of 3 months. Dr Loveridge will continue to provide significant strategic advice for the Company's Phase III clinical trial, Company operations, intellectual property and commercial/clinical partnerships including with Pepton.

Although some additional headcount will be required as the Company commences its Phase III clinical trial, the Board believes the current senior executive and Board structure/remuneration is appropriate based on the Company's size, operating plan and clinical activities.

It remains the Company's intention in order to retain and incentivise key personnel, to issue long term performance securities and will obtain shareholder approval as required.

The material terms of the Director Agreements are shown in Appendix 1, in accordance with Listing Rule 3.16.4.

- ENDS -

*This release dated 31 January 2022 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics.*

---

## For more information, please contact:

### Company/Investors

Dr Thomas Duthy

Executive Director

[tduthy@invextherapeutics.com](mailto:tduthy@invextherapeutics.com)

+61 402 493 727

### Media

Margie Livingston

Ignite Communications

[margie@ignitecommunications.com.au](mailto:margie@ignitecommunications.com.au)

+61 438 661 131

To subscribe to Invex email alerts, please visit [www.invextherapeutics.com](http://www.invextherapeutics.com) and follow us on Twitter [@InvexThera\\_ASX](https://twitter.com/InvexThera_ASX)

## About Invex Therapeutics Ltd

---

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. [www.invextherapeutics.com](http://www.invextherapeutics.com).

## About Presendin™

---

Presendin™ is a once per week, sub cutaneous, sustained-release (SR) Exenatide microsphere formulation originally developed by Peptron, Inc. (KOSDAQ: 087010). In September 2021 Invex entered into an exclusive collaboration, manufacturing and supply agreement with Peptron for Presendin™ in IIH for all major markets, with the exception of South Korea.

Exenatide is a small peptide and a synthetic version of the GLP-1 agonist exendin-4, which is currently approved for the treatment of type 2 diabetes. In 2017, Invex received orphan drug designation for Exenatide in IIH from the US Food and Drug Administration and European Medicines Agency.

## Appendix 1

### Summary of Material Terms and Conditions of Employment of Professor Alexandra Sinclair

<b>Commencement Date as Chief Scientific Officer (CSO) and Executive Director</b>	1 March 2022
<b>Term</b>	No fixed term, ongoing until terminated by either party in accordance with the employment contract.
<b>Position</b>	3 days per week (0.6 FTE)
<b>Fixed Remuneration</b>	£145,000 per annum, plus £1,320 per annum employer pension contribution
<b>Short Term Incentives</b>	No benefits other than remuneration except as incurred in normal operations of the business
<b>Long Term Incentives</b>	Participation in the Invex Employee Securities Incentive Plan
<b>Notice Period</b>	Either party may terminate the employment contract by providing not less than 3 months' notice.

### Summary of Material Terms and Conditions of Consultancy with Dr Jason Loveridge

<b>Non-Executive Chairman / Consultant</b>	1 February 2022
<b>Term</b>	No fixed term, ongoing until terminated by either party in accordance with the consultancy agreement.
<b>Fixed Remuneration</b>	£110,000 per annum consultancy fee with Warambi, and Non-Executive Chairman fee of \$60,000 per annum
<b>Short Term Incentives</b>	No benefits other than remuneration except as incurred in normal operations of the business
<b>Long Term Incentives</b>	Participation in the Invex Employee Securities Incentive Plan
<b>Notice Period</b>	Dr Loveridge may terminate the contract by providing 30 days' notice. Invex may terminate with 90 days' notice.